The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Feb. 26, 2018
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Nicholas J. Papadopoulos, LaGrangeville, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Gavin Thurston, Briarcliff Manor, NY (US);

Ella Ioffe, Bronx, NY (US);

Elena Burova, Mount Kisco, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 15/13 (2006.01); C12N 15/63 (2006.01); A61K 39/395 (2006.01); A61N 5/10 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61N 5/10 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.


Find Patent Forward Citations

Loading…